India’s bio-based economy may likely to reach to US$ 100 billion in size by 2025
India is home to the world’s leading vaccine and pharmaceutical companies. Every 2 out of 3 children in the developing world are immunized with vaccines manufactured in India.
Non-Hodgkin’s Lymphoma (NHL) is the most common hematologic malignancy and the tenth most common cancer worldwide, with nearly 510,000 new cases diagnosed in 2018. It accounts for nearly 249,000 deaths worldwide in 2018.
Inhaled vaccines aim to fight Coronavirus at its point of attack.
Millions of people across the globe going into poverty due to Covid-19 pandemic.
A Phase I clinical trial to test an intranasal COVID-19 vaccine spray has been given regulatory approval in China.
There has been a 20 per cent rise in patients suffering from advanced cardiac complications as they are not visiting hospitals due to the fear of contracting Covid-19.
The global pharmaceutical logistics market is expected to rise with CAGR of 7.3% from 2020 to 2027. In 2019, it was valued at USD 69.0 billion.
The US pharmaceutical sector, who’s combined annual research and development budget is more than USD 45 billion.
The FDA defines a rare paediatric disease as a serious or life-threatening disease in which the disease manifestations primarily affect individuals aged from birth to 18 years.
NephroPlus, one of the largest dialysis care in India, has acquired majority stake in Royal Care Dialysis Centers, Inc (RCDC), a reputed dialysis network in the Philippines.
India will have great opportunity to play a critical role in biopharma research and development process.
India has been recognized as the ‘Pharmacy of the World’, as over 120 countries got some essential medicines.
Approx there are more than150 million users in India uses Aarogya Setu app.